ARTICLE | Clinical News
CD22 epratuzumab antibody regulatory update
February 20, 2001 8:00 AM UTC
IMMU received U.S. Patent No. 6,187,287 covering humanized and chimerized forms of its CD22 antibody, which is in Phase III trials to treat low-grade non-Hodgkin's lymphoma. ...